Jonsson Comprehensive Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Jonsson Comprehensive Cancer Center sits in the top decile of US sponsors by registered trial count (#111 of 15,742 sponsors by registered trial count).
Jonsson Comprehensive Cancer Center: 321 sponsored US clinical trials, 61 recruiting.
Jonsson Comprehensive Cancer Center sponsors 321 registered US clinical trials on ClinicalTrials.gov, 61 of them currently recruiting, and 164 completed. 13 of these trials are in Phase 3-4 (later-stage) and 206 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Carcinoma, with 10 trials.
Top-decile sponsor footprint
Jonsson Comprehensive Cancer Center ranks in the top decile of sponsors by registered trial count (#111 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
164 of 203 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
321 total, page 2 of 7
Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer
NCT04703101
Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
NCT04469764
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
NCT04553770
Interstitial Brachytherapy for the Treatment of Unresectable/Unablatable Kidney Cancer
NCT04473781
A Study to See if an iPhone Weight Management App Can Help Promote Weight Loss in Adolescents and Young Adults After a Stem Cell Transplant
NCT04453072
Brain Health in Breast Cancer Survivors
NCT04297020
Development of Liquid Biopsy Technologies for Noninvasive Cancer Diagnostics in Patients With Suspicious Thyroid Nodules or Thyroid Cancer
NCT04742608
Pembrolizumab in Treating Participants With Leukoplakia
NCT03603223
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
NCT02701153
Germ-Line Mutations in Blood and Saliva Samples From Patients With Cancer
NCT02280161
Active Surveillance for Cancer of the Prostate (ASCaP)
NCT00949819
A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric Glioma
NCT06342908
Registry of Patients Undergoing Cryoablation for Early Stage Breast Cancer
NCT06387173
Psychoeducation for Uveal Melanoma
NCT06075589
Malnutrition Screening and Dietary Intervention to Improve Nutrition Outcomes in Patients With Unresectable Pancreatic Cancer
NCT06090916
177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study
NCT05496959
Pea Protein Oral Nutrition Supplement for the Reduction of Gastrostomy Tube Placement Rate in Patients With Locally Advanced Head and Neck Cancer Undergoing Chemoradiation Therapy
NCT05115760
Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy
NCT05160597
Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma
NCT05045027
Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer
NCT03902951
Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer
NCT04285671
Germline DNA-Based Radiosensitivity Biomarker Influence on Toxicity Following Prostate Radiotherapy, GARUDA Trial
NCT04624256
Micro-Ultrasound for the Detection and Localization of Prostate Cancer Tumors in Patients Undergoing Radical Prostatectomy
NCT04299620
Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma
NCT04420975
Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation
NCT04457232
68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma
NCT04457258
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
NCT04459273
Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies
NCT04395079
Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma
NCT04299113
CT-guided Stereotactic Body Radiation Therapy and MRI-guided Stereotactic Body Radiation Therapy for Prostate Cancer, MIRAGE Study
NCT04384770
Focal Laser Ablation of Prostate Cancer
NCT04305925
Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma
NCT04201873
Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
NCT04147494
Implementation Research to Increase Colorectal Cancer Screening Rates Among Low Income and Ethnic Minority Groups
NCT06090643
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia
NCT04007029
CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer
NCT03546361
CPX-351 Plus Enasidenib for Relapsed AML
NCT03825796
Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer
NCT03732950
Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy
NCT03830918
Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery
NCT03541850
Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate
NCT03582475
SPECT/CT for the Characterization of Renal Masses
NCT03996850
Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer
NCT03672773
Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer
NCT03601455
Multicenter Randomized Trial of 68Ga-PSMA-11 PET/CT Based SRT After Radical Prostatectomy
NCT03582774
Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer
NCT02881242
Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body Radiotherapy
NCT03148327
Soylent in Reducing Gastrostomy Tube Rates in Patients With Locally Advanced Head and Neck Cancer Undergoing Chemoradiotherapy
NCT07242365
Randomized Trial Comparing Performance of Molecular Markers for Indeterminate Thyroid Nodules
NCT02681328
Low-Fat Diet and Fish Oil in Men on Active Surveillance for Prostate Cancer
NCT02176902
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 106 |
| Phase 2 | 100 |
| Phase 3 | 12 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Jonsson Comprehensive Cancer Center pipeline
61 recruiting of 321 indexed (19% open); 164 completed (51%).
Phase mix: 13 late (III/IV) vs 206 early (I/II) (early-phase heavy).
Top condition: Prostate Carcinoma (10 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Jonsson Comprehensive Cancer Center: open-pipeline peers nationwide
Peers matched on 321 registered trials and 19% open enrollment, not the therapeutic-area sidebar.
Jonsson Comprehensive Cancer Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 321 trials (± recruiting share)
- Rush University Medical Center · 320 trials · 17% recruiting
- University of Arkansas · 318 trials · 12% recruiting
- Allergan · 314 trials · 0% recruiting
- Genentech · 332 trials · 7% recruiting
Sponsors near 19% open enrollment (± trial volume)
- MemorialCare Health System · 19% recruiting · 21 trials
- University of North Texas Health Science Center · 19% recruiting · 21 trials
- University of Wisconsin, Milwaukee · 19% recruiting · 21 trials
- Verastem · 19% recruiting · 21 trials
Related
What to do with this Jonsson Comprehensive Cancer Center page
321 registered trials is a research-attention snapshot, not an endorsement of Jonsson Comprehensive Cancer Center or any single study.
- 61 of Jonsson Comprehensive Cancer Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Carcinoma is the condition Jonsson Comprehensive Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Carcinoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Jonsson Comprehensive Cancer Center pipeline card: 321 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.